Loading
4D Molecular Therapeutics, Inc. Stock: price and insider trades · United States
US·Mcap US$674M
No insider purchase over the last 90 days. The latest was filed 11 May 2023.
4D Molecular Therapeutics, Inc.: what insiders have been doing
This page follows insider dealings at 4D Molecular Therapeutics, Inc. as filed with SEC (Form 4) based in United States. Over the twelve months to 18 October 2026, 51 filings were filed, from 6 insiders.
Only sales appear on the open market, 22 sales in all totalling €3.4M, filed by 3 insiders. The totals exclude 3 filings filed without an amount. One trade stands out by size: a sale of €700k from Kirn David, disclosed on 16 September 2026, or 0.098% of market capitalisation.
Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 51 filings here. Our records for 4D Molecular Therapeutics, Inc. go back to 2021, with 1 purchase and 37 sales on the open market in total. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 85.2 m USD and net income at -140.1 m USD.
Other companies in the same market with recent insider buying flagged by our signals: GameStop Corp. and Heico Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
95
Thresholds
n/a
Buy Volume
€12M
1 ops. · all time
Sell Volume
€18M
37 ops. · all time
Who traded when
BuySaleDavid Kirn12 sales
Scott Bizily8 sales
Gupta Ashoo4 sales
Since the insiders bought
- +42.8%Entry US$17.91 · Close at T+365 US$25.57
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate 4D Molecular Therapeutics, Inc. Strong Buy (bullish), based on 11 analysts. Average price target: US$28.09.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$12.20
Analyst consensus
11 analystsStrong buy
US$18.00Target US$28.09(+130%)US$37.00
Income statement
RevenueUS$85.2M
EBITDA-US$151.9M-178% margin
Net income-US$140.1M-194.7% margin
Valuation
PER (forward)-3.0x
P/Book1.7x
Beta2.74
Balance sheet & cash
Market capUS$674M
Total debtUS$21.4M
Free Cash Flow-US$109.6M
Debt / Equity10%
Profitability & ownership
ROE-43.3%
ROA-25.1%
% insiders2.7%
% institutions106.1%
Last declaration on 7 October 2026
Declarations95 total
58,061 shares@ US$12.92150.094% mcap8.4% of flowCommon StockSEC:0001193125-26-417068:0
272 shares@ US$13.61040.0005% mcap0.0% of flowCommon StockSEC:0001193125-26-417068:1
58,333 shares@ US$12.920.094% mcap15.2% of flowClass A CommonSEC144:0001958244-26-000638
1,635 shares@ US$4.140.0008% mcap1.1% of flowCommon StockSEC:0001193125-26-398204:0
1,635 shares@ US$13.650.0027% mcap3.5% of flowCommon StockSEC:0001193125-26-398204:1
58,333 shares@ US$13.9030.098% mcap9.7% of flowCommon StockSEC:0001193125-26-393243:0
58,333 shares@ US$13.760.097% mcap18.5% of flowClass A CommonSEC144:0001958244-26-000601
584 shares@ US$6.490.0005% mcap0.6% of flowCommon StockSEC:0001193125-26-382245:0
584 shares@ US$14.000.0010% mcap1.3% of flowCommon StockSEC:0001193125-26-382245:1
50,000 shares@ US$4.140.025% mcap2.5% of flowCommon StockSEC:0001193125-26-361096:0
43,149 shares@ US$15.35660.080% mcap7.9% of flowCommon StockSEC:0001193125-26-361096:1
25,927 shares@ US$16.41730.051% mcap5.1% of flowCommon StockSEC:0001193125-26-361096:2
69,076 shares@ US$16.760.14% mcap26.8% of flowClass A CommonSEC144:0001958244-26-000539
6,540 shares@ US$12.190.0096% mcap27.6% of flowCOMMONSEC144:0001950047-26-008269
1,635 shares@ US$4.140.0008% mcap1.1% of flowCommon StockSEC:0001193125-26-354313:0
1,635 shares@ US$12.000.0024% mcap3.1% of flowCommon StockSEC:0001193125-26-354313:1
1,635 shares@ US$4.140.0008% mcap1.1% of flowCommon StockSEC:0001193125-26-354313:2
1,635 shares@ US$12.200.0024% mcap3.1% of flowCommon StockSEC:0001193125-26-354313:3
1,635 shares@ US$11.870.0024% mcap6.7% of flowCOMMONSEC144:0001950047-26-008088
26,842 shares@ US$10.23010.033% mcap3.3% of flowCommon StockSEC:0001193125-26-335115:0
26,842 shares@ US$10.260.033% mcap6.4% of flowClass A CommonSEC144:0001958244-26-000477
12,415 shares@ US$10.04610.015% mcap1.5% of flowCommon StockSEC:0001193125-26-333014:0
12,415 shares@ US$10.090.015% mcap2.9% of flowClass A CommonSEC144:0001958244-26-000473
42,608 shares@ US$12.86560.067% mcap6.6% of flowCommon StockSEC:0001834021-26-000004:0
442 shares@ US$12.83550.0007% mcap0.1% of flowCommon StockSEC:0001834021-26-000004:2
25 of 95 declarations
About 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapies for genetic diseases. It utilizes a viral vector technology platform to design targeted treatments.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
